Biogen (BIIB)
(Real Time Quote from BATS)
$233.28 USD
-0.85 (-0.36%)
Updated Jun 5, 2024 10:50 AM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 761 - 780 ( 803 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
What Was Supposed to Be a Quiet Week Turns Into a Busy Week
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on MS drugs, such as BG-12, raises hopes of improvement in growth prospects
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Encouraging data on MS drugs, such as BG-12, raises hopes of an improvement in growth prospects...
Provider: FIRST GLOBAL
Analyst: THOMAS K